Provider review · Updated September 29, 2026
Keck Medicine of USC testosterone records: the treatment purpose is not the formulation
Keck’s center describes low-testosterone care alongside fertility and sexual-health procedures. A clinical goal or procedure name does not identify a medicine’s complete contents.
Editorial research from public documents. No patient testing or clinician review is claimed.
Keck Medicine of USC’s Fertility and Men’s Sexual Health Center addresses several concerns that can overlap in a person’s life. Its account includes low testosterone, fertility, sexual function and different procedures. Understanding the purpose of care is valuable, but that purpose does not tell a reader what is inside a particular medicine.
We examined the center’s public record with FDA and professional references on September 29, 2026. This review looks at the relationship between clinical goals, treatment terminology and product identity. It is not a report of receiving care, an endorsement of the center or evidence of a personal prescription.
The center identifies a relevant clinical role
The Keck service page explicitly includes low testosterone and hypogonadism. It describes listening to concerns and collaborating on a plan from consultation through follow-up. These statements establish a clinical service, although they do not document what occurred in an individual encounter.
The OHSU medicine-record review considers another service that links hormone expertise with investigating the underlying concern. The useful comparison is the kind of information each page provides. Neither a collaborative approach nor a clinician’s expertise identifies the manufacturer, complete formulation or particular medicine information associated with someone’s care. Those facts require a different record from the institutional description.
Keep the fertility goal identifiable
Keck’s center description spans fertility and sexual-health care. A shared setting does not mean a therapy discussed for one concern answers every other concern. The purpose of an assessment should remain visible rather than becoming a generic statement that hormones were addressed.
The Endocrine Society guideline summary includes a caution against testosterone treatment in men planning fertility in the near term. This is professional context, not a conclusion about a reader. It helps explain why a treatment goal and a medicine name cannot substitute for one another. The public center page cannot establish that an individual reproductive goal has been evaluated or resolved.
A procedure list is not an ingredient list
The Keck page lists procedures for several different clinical concerns, including testosterone treatment categories and injections used in other settings. Reading them as one undifferentiated medication list would erase the distinctions between those subjects.
A procedure name can describe a clinical activity without specifying the complete preparation associated with it. Our excipients guide examines why the contents of an actual medicine require their own evidence. This review does not infer cypionate, a particular vehicle or other ingredients from the presence of an injection procedure on the center’s website. It also does not turn that list into a way to obtain a selected product.
Approved generic has a narrower meaning than familiar ingredient
The FDA generic-drug record explains the relationship between an approved generic and its reference medicine. Approval requires defined characteristics and evidence, including pharmaceutical equivalence and bioequivalence. The term therefore carries more information than a statement that a preparation contains a familiar hormone.
Nothing in the Keck service description establishes that regulatory relationship for an individual product. A compounded preparation should not acquire approved-generic status through association with an institution or an active-ingredient name. The UW Medicine review examines the parallel difference between discussing benefits and risks clinically and identifying what FDA reviewed for a particular medicine. These are related but distinct documentary questions.
The approved use remains a separate fact
FDA’s off-label explanation distinguishes an approved product from a use outside its approved labeling. A clinician may consider an unapproved use in individual care, but FDA has not thereby determined the medicine safe and effective for that use. This review does not claim that Keck follows any particular off-label practice.
The route-and-label guide explores why use and product must both be identified. A goal such as addressing a symptom cannot, on its own, establish an approved indication, a route or an exact preparation. Nor can off-label terminology turn an unapproved compounded drug into an FDA-approved product. The underlying identity question must remain explicit.
A clinical aspiration is not product evidence
Keck’s public account uses broad language about treatment effectiveness, safety and positive changes. This review does not treat those statements as measured outcomes for an individual or as evidence about a particular formulation. A center’s description of its approach cannot replace a product-specific benefit-and-risk record.
The July 2026 professional statement retains long-term evidence gaps and the importance of accurate assessment. Our age-related hormone guide separates that clinical context from assumptions based on age. Understanding why care is being considered still does not identify the medicine, and a recognizable medicine name does not establish that the original concern will improve.
Preserve the question that each document can answer
FDA’s inactive-ingredient FAQ makes clear that database information concerns approved finished products and particular formulation contexts. It cannot reveal the contents of an unexamined medicine. That is a useful final distinction alongside Keck’s broad clinical description.
The service record can establish a center’s relevant work. A clinical explanation can describe the concern being addressed. The actual medicine information can identify the preparation and its contents. This review connects those categories without pretending they are interchangeable. Keeping them separate allows a reader to recognize what the public evidence contributes while leaving individual product identification and clinical judgment to the records and professionals able to establish them.
Source notes
These links identify the records used in this article. A claim about one named medicine does not describe every product with the same ingredient.
- Keck Medicine of USC: Fertility and Men’s Sexual Health CenterOfficial fertility and men’s sexual-health clinical service. Different procedure descriptions retain their clinical subjects; broad effectiveness and safety language is not evidence of an individual outcome or exact formulation. · Checked 2026-09-29
- Endocrine Society: Testosterone Therapy for Hypogonadism Guideline Resources (2018)2018 professional guideline resource and recommendation summary; clinical diagnosis, cause and fertility context, not an institution-specific protocol or personal treatment instruction. · Checked 2026-09-29
- FDA: Generic Drugs — Questions & AnswersFDA explanation of approved generic-drug standards, reference products, bioequivalence and allowable differences. No approval or equivalence is inferred for an uninspected preparation; inactive-ingredient differences do not predict personal tolerability. · Checked 2026-09-29
- FDA: Understanding Unapproved Use of Approved DrugsFDA patient explanation of an approved drug used outside approved labeling. Clinical consideration does not establish FDA approval of that use or confer approval on a compounded preparation; no individual use or route is selected. · Checked 2026-09-29
- Endocrine Society: Statement on Testosterone Replacement Therapy (July 16, 2026)Professional statement dated July 16, 2026; accurate diagnosis, multiple symptom contributors and continuing long-term uncertainty remain separate from medicine identity and individual eligibility. · Checked 2026-09-29
- FDA: Inactive Ingredients in Approved Drug Products — FAQFDA database FAQ for ingredients in approved finished products, with route and dosage-form context. Database presence or a substance identifier does not establish the contents, approval, stability or personal suitability of an unseen preparation; no exposure calculations are used. · Checked 2026-09-29